Table 1.
Consented patients (N) | 149 |
Treated patients [N (% of consented patients)] | 83 (55.7%) |
Patients with ≥1 matched treatment [N (% of consented patients)] | 73 (49.0%) |
Patients with no matched treatments administered [N (% of consented patients)] | 10 (6.7%) |
Age1 (Median, 95% CI, Range) | 62 (59–65, 21–86) |
Gender1 [N (%)] | |
Women | 55 (66.3%) |
Men | 28 (33.7%) |
Ethnicity1 [N (%)] | |
Caucasian | 67 (80.7%) |
Asian | 4 (4.8%) |
African American | 1 (1.2%) |
Other or unknown | 11 (13.3%) |
Tumor type1 [N (%)] | |
Gastrointestinal & hepatopancreatobiliary | 35 (42.2%) |
Gynecologic | 14 (16.9%) |
Breast | 12 (14.5%) |
Central nervous system (CNS) | 6 (7.2%) |
Genitourinary | 3 (3.6%) |
Head and neck | 3 (3.6%) |
Lung | 3 (3.6%) |
Other2 | 7 (8.4%) |
Number of total genomic alterations1 (Median, Range; VUS excluded) | 5 (1–19) |
Number of administered drugs1 (Median, Range) | 2 (1–5) |
Median number of prior therapies in the metastatic setting1 (Median, IQR) | 2 (1–3) |
Parameters shown are for the 83 treated patients (N=83).
Other included liposarcoma (N=2); carcinoma of the skin, neuroendocrine carcinoma, fibromyxoid sarcoma, bone marrow multiple myeloma, and paraganglioma (N=1 each).
Abbreviations: CI = Confidence Interval; IQR = interquartile range: N=number; VUS = variant of unknown significance.